CPDR Biospecimen Banks
New Challenges in Predicting the Clinical Course for CaP Patients
It is worth noting that well-characterized biospecimens from our group and others have already contributed immensely to the novel molecular discoveries made in the field of CaP research. Therefore, with a proven track record, the continued development and enhancement of the CPDR Biospecimen Bank holds great promise for much needed translational research at CPDR and at other institutions through collaborative research agreements.
The biospecimen storage and processing facilities that comprise the CPDR Biospecimen Bank are housed in four locations: the Walter Reed National Military Medical Center (WRNNMC) in Bethesda, MD; the headquarters of the Center for Prostate Disease Research (CPDR) in Rockville, MD; the Joint Pathology Center (JPC) in Washington, DC, and the Prostate Cell Center at the Department of Surgery of the Uniformed Services University (USU) in Bethesda, MD. These facilities have been processing biospecimens since 1993 and have a significant endowment of biospecimen resources. The biospecimen resources and analytical and processing services provided by these facilities have supported numerous studies conducted at the CPDR. These studies have resulted in over 60 peer-reviewed publications, 10 grants or CRADA, and five patents to date.
- Radical Prostatectomy Specimen Processing for Frozen Tissue Bank Generation
- Histological Characterization
- Radical Prostatectomy Specimen Processing for Fixed, Paraffin-embedded Tissue Bank Generation
- Laser Capture Microdissection (LCM) of Prostate Tissues and Generation of
LCM/RNA and Genomic DNA Bank
- Development of Tissue Microarrays (TMA)
- Peripheral Blood Collection and Processing to Generate Serum and genomic DNA Banks
- Serum Preparation
- Peripheral Blood DNA Bank
More recently, active collaborations have been sought by corporate partners and academic leaders to use CPDR Bio-specimens bank. A Biospecimen Oversight Committee and Research Opportunity Evaluation Committee have been instituted recently to monitor the prioritization of bio-specimens for in-house use and collaborations.
September 29, 2014
Genomic Health Announces Positive Results from Latest Clinical Validation Study of Oncotype DX® as Predictor of Near- and Long-term Outcomes in Racially Diverse Group of Prostate Cancer Patients
REDWOOD CITY, CA – Genomic Health, Inc. (Nasdaq: GHDX) today announced strongly positive results from an additional independent clinical validation study of the Oncotype DX® prostate cancer test, conducted in collaboration with the Uniformed Services University of the Health Sciences' (USU) Center for Prostate Disease Research (CPDR) supported by a multi-disciplinary team of investigators under a cooperative research and development agreement with USU. This new large study reconfirmed the biopsy-based test's Genomic Prostate Score (GPS) as a predictor of adverse pathology at surgery and, for the first time, validated GPS as a strong independent predictor of a rise in prostate-specific antigen (PSA) following surgery (biochemical recurrence).
Read Full Article.
Read Publication - European Urology
Read the NOVEMEBR 2014 Newsletter